Equine Pituitary Pars Intermedia Dysfunction

Veterinary Clinics of North America - Equine Practice

Volumn 27, Issue 1, 2011, Pages 93-113

  McFarlane, Dianne ^a  

^a OKLAHOMA STATE UNIVERSITY   (United States)

Author keywords

Adrenal; Cushing's; Horse; Hypothalamus; Laminitis; Pituitary

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; PERGOLIDE;

AGING; ANIMAL; ANIMAL DISEASE; DIET; FEMALE; HISTOLOGY; HORSE; HORSE DISEASE; HYPOPHYSIS DISEASE; HYPOPHYSIS INTERMEDIATE LOBE; MALE; PATHOPHYSIOLOGY; REVIEW;

AGING; ANIMALS; DIET; DOPAMINE AGONISTS; FEMALE; HORSE DISEASES; HORSES; MALE; PERGOLIDE; PITUITARY DISEASES; PITUITARY GLAND, INTERMEDIATE;

EQUIDAE;

EID: 79952358369     PISSN: 07490739     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cveq.2010.12.007     Document Type: Review

References (103)

1. Schott H.C. Pituitary pars intermedia dysfunction: equine Cushing's disease. Vet Clin North Am Equine Pract 2002, 18:237-270.
2. Masson-Pevet M., Gauer F. Seasonality and melatonin receptors in the pars tuberalis in some long day breeders. Biol Signals 1994, 3:63-70.
3. Wilson M.G., Nicholson W.E., Holscher M.A., et al. Proopiolipomelanocortin peptides in normal pituitary, pituitary tumor, and plasma of normal and Cushing's horses. Endocrinology 1982, 110:941-954.
4. Saiardi A., Borrelli E. Absence of dopaminergic control on melanotrophs leads to Cushing's-like syndrome in mice. Mol Endocrinol 1998, 12:1133-1139.
5. Ham J., Smyth D.G. Regulation of bioactive beta-endorphin processing in rat pars intermedia. FEBS Lett 1984, 175:407-411.
6. Millington W.R., Dybdal N.O., Mueller G.P., et al. N-acetylation and C-terminal proteolysis of beta-endorphin in the anterior lobe of the horse pituitary. Gen Comp Endocrinol 1992, 85:297-307.
7. Wilkinson C.W. Roles of acetylation and other post-translational modifications in melanocortin function and interactions with endorphins. Peptides 2006, 27:453-471.
8. Getting S.J. Targeting melanocortin receptors as potential novel therapeutics. Pharmacol Ther 2006, 111:1-15.
9. Cummings D.E., Schwartz M.W. Melanocortins and body weight: a tale of two receptors. Nat Genet 2000, 26:8-9.
10. Lipton J.M., Glyn J.R., Zimmer J.A. ACTH and alpha-melanotropin in central temperature control. Fed Proc 1981, 40:2760-2764.
11. Murphy M.T., Richards D.B., Lipton J.M. Antipyretic potency of centrally administered alpha-melanocyte stimulating hormone. Science 1983, 221:192-193.
12. Lipton J.M., Catania A. Anti-inflammatory actions of the neuroimmunomodulator alpha-MSH. Immunol Today 1997, 18:140-145.
13. Catania A., Rajora N., Capsoni F., et al. The neuropeptide alpha-MSH has specific receptors on neutrophils and reduces chemotaxis in vitro. Peptides 1996, 17:675-679.
14. Oktar B.K., Yuksel M., Alican I. The role of cyclooxygenase inhibition in the effect of alpha-melanocyte-stimulating hormone on reactive oxygen species production by rat peritoneal neutrophils. Prostaglandins Leukot Essent Fatty Acids 2004, 71:1-5.
15. Beloff-Chain A., Morton J., Dunmore S., et al. Evidence that the insulin secretagogue, beta-cell-tropin, is ACTH 22-39. Nature 1983, 301:255-258.
16. Marshall J.B., Kapcala L.P., Manning L.D., et al. Effect of corticotropin-like intermediate lobe peptide on pancreatic exocrine function in isolated rat pancreatic lobules. J Clin Invest 1984, 74:1886-1889.
17. Orth D.N., Holscher M.A., Wilson M.G., et al. Equine Cushing's disease: plasma immunoreactive proopiolipomelanocortin peptide and cortisol levels basally and in response to diagnostic tests. Endocrinology 1982, 110:1430-1441.
18. McFarlane D., Beech J., Cribb A. Alpha-melanocyte stimulating hormone release in response to thyrotropin releasing hormone in healthy horses, horses with pituitary pars intermedia dysfunction and equine pars intermedia explants. Domest Anim Endocrinol 2006, 30:276-288.
19. Saland L.C. The mammalian pituitary intermediate lobe: an update on innervation and regulation. Brain Res Bull 2001, 54:587-593.
20. Danger J.M., Perroteau I., Franzoni M.F., et al. Innervation of the pars intermedia and control of alpha-melanotropin secretion in the newt. Neuroendocrinology 1989, 50:543-549.
21. Shioda S., Nakai Y., Hori T., et al. Innervation of thyrotropin-releasing hormone-containing neurons in the bullfrog pars intermedia. Neurosci Lett 1987, 81:53-56.
22. McFarlane D., Donaldson M.T., McDonnell S.M., et al. Effects of season and sample handling on measurement of plasma alpha-melanocyte-stimulating hormone concentrations in horses and ponies. Am J Vet Res 2004, 65:1463-1468.
23. Logan A., Weatherhead B. Photoperiodic dependence of seasonal changes in pituitary content of melanocyte-stimulating hormone. Neuroendocrinology 1980, 30:309-312.
24. Lincoln G.A., Rhind S.M., Pompolo S., et al. Hypothalamic control of photoperiod-induced cycles in food intake, body weight, and metabolic hormones in rams. Am J Physiol Regul Integr Comp Physiol 2001, 281:R76-R90.
25. Schuhler S., Ebling F.J. Role of melanocortin in the long-term regulation of energy balance: lessons from a seasonal model. Peptides 2006, 27:301-309.
26. Place N.J., McGowan C.M., Lamb S.V., et al. Seasonal variation in serum concentrations of selected metabolic hormones in horses. J Vet Intern Med 2010, 24:650-654.
27. Donaldson M.T., McDonnell S.M., Schanbacher B.J., et al. Variation in plasma adrenocorticotropic hormone concentration and dexamethasone suppression test results with season, age, and sex in healthy ponies and horses. J Vet Intern Med 2005, 19:217-222.
28. McFarlane D., Paradis M.R., Zimmel D., et al. The effect of latitude of residence, breed and pituitary dysfunction on seasonal plasma ACTH and MSH concentration [abstract]. J Vet Intern Med 2010, 24:689.
29. Frank N., Elliott S.B., Chameroy K.A., et al. Association of season and pasture grazing with blood hormone and metabolite concentrations in horses with presumed pituitary pars intermedia dysfunction. J Vet Intern Med 2010, 24(5):1167-1175.
30. Donaldson M.T., Jorgensen A.J., Beech J. Evaluation of suspected pituitary pars intermedia dysfunction in horses with laminitis. J Am Vet Med Assoc 2004, 224:1123-1127.
31. Hoffman R.M., Wilson J.A., Kronfeld D.S., et al. Hydrolyzable carbohydrates in pasture, hay, and horse feeds: direct assay and seasonal variation. J Anim Sci 2001, 79:500-506.
32. Brosnahan M.M., Paradis M.R. Assessment of clinical characteristics, management practices, and activities of geriatric horses. J Am Vet Med Assoc 2003, 223:99-103.
33. McGowan T.W. Aged horse health, management and welfare 2008, [doctoral thesis], University of Queensland, St Lucia, Australia.
34. Hillyer M.H., Taylor F.R., Mair T.S., et al. Diagnosis of hyperadrenocorticism in the horse. Equine Vet Educ 1992, 4:131-134.
35. van der Kolk J.H., Kalsbeek H.C., van Garderen E., et al. Equine pituitary neoplasia: a clinical report of 21 cases (1990-1992). Vet Rec 1993, 133:594-597.
36. Couetil L., Paradis M.R., Knoll J. Plasma adrenocorticotropin concentration in healthy horses and in horses with clinical signs of hyperadrenocorticism. J Vet Intern Med 1996, 10:1-6.
37. Schott HC, Coursen CL, Eberhart SW, et al. The Michigan Cushing's project. In: Proceedings of the 47th Annual Convention of the American Association of Equine Practitioners. 2001. p. 22-4.
38. Donaldson M.T., LaMonte B.H., Morresey P., et al. Treatment with pergolide or cyproheptadine of pituitary pars intermedia dysfunction (equine Cushing's disease). J Vet Intern Med 2002, 16:742-746.
39. Perkins G.A., Lamb S., Erb H.N., et al. Plasma adrenocorticotropin (ACTH) concentrations and clinical response in horses treated for equine Cushing's disease with cyproheptadine or pergolide. Equine Vet J 2002, 34:679-685.
40. McGowan C.M., Neiger R. Efficacy of trilostane for the treatment of equine Cushing's syndrome. Equine Vet J 2003, 35:414-418.
41. Munoz M.C., Doreste F., Ferrer O., et al. Pergolide treatment for Cushing's syndrome in a horse. Vet Rec 1996, 139:41-43.
42. Sgorbini M., Panzani D., Maccheroni M., et al. Equine Cushing-like syndrome: diagnosis and therapy in two cases. Vet Res Commun 2004, 28(Suppl 1):377-380.
43. Chandler K.J., Dixon R.M. Urinary cortisol:creatinine ratios in healthy horses and horses with hyperadrenocorticism and non-adrenal disease. Vet Rec 2002, 150:773-776.
44. McFarlane D., Holbrook T.C. Cytokine dysregulation in aged horses and horses with pituitary pars intermedia dysfunction. J Vet Intern Med 2008, 22:436-442.
45. Heinrichs M., Baumgartner W., Capen C.C. Immunocytochemical demonstration of proopiomelanocortin-derived peptides in pituitary adenomas of the pars intermedia in horses. Vet Pathol 1990, 27:419-425.
46. Frank N., Andrews F.M., Sommardahl C.S., et al. Evaluation of the combined dexamethasone suppression/thyrotropin-releasing hormone stimulation test for detection of pars intermedia pituitary adenomas in horses. J Vet Intern Med 2006, 20:987-993.
47. Boujon C.E., Bestetti G.E., Meier H.P., et al. Equine pituitary adenoma: a functional and morphological study. J Comp Pathol 1993, 109:163-178.
48. Wright W.A., Evanoff B.A., Lian M., et al. Geographic and ethnic variation in Parkinson disease: a population-based study of US Medicare beneficiaries. Neuroepidemiology 2010, 34:143-151.
49. Lanska D.J. The geographic distribution of Parkinson's disease mortality in the United States. J Neurol Sci 1997, 150:63-70.
50. Priyadarshi A., Khuder S.A., Schaub E.A., et al. Environmental risk factors and Parkinson's disease: a metaanalysis. Environ Res 2001, 86:122-127.
51. McFarlane D. Advantages and limitations of the equine disease, pituitary pars intermedia dysfunction as a model of spontaneous dopaminergic neurodegenerative disease. Ageing Res Rev 2007, 6:54-63.
52. Millington W.R., Dybdal N.O., Dawson R., et al. Equine Cushing's disease: differential regulation of beta-endorphin processing in tumors of the intermediate pituitary. Endocrinology 1988, 123:1598-1604.
53. McFarlane D., Dybdal N., Donaldson M.T., et al. Nitration and increased alpha-synuclein expression associated with dopaminergic neurodegeneration in equine pituitary pars intermedia dysfunction. J Neuroendocrinol 2005, 17:73-80.
54. Gehlert D.R., Bishop J.F., Schafer M.P., et al. Rat intermediate lobe in culture: dopaminergic regulation of POMC biosynthesis and cell proliferation. Peptides 1988, 9(Suppl 1):161-168.
55. Goudreau J.L., Lindley S.E., Lookingland K.J., et al. Evidence that hypothalamic periventricular dopamine neurons innervate the intermediate lobe of the rat pituitary. Neuroendocrinology 1992, 56:100-105.
56. Engler D., Pham T., Liu J.P., et al. Studies of the regulation of the hypothalamic-pituitary-adrenal axis in sheep with hypothalamic-pituitary disconnection. II. Evidence for in vivo ultradian hypersecretion of proopiomelanocortin peptides by the isolated anterior and intermediate pituitary. Endocrinology 1990, 127:1956-1966.
57. Glover C.M., Miller L.M., Dybdal N.O., et al. Extrapituitary and pituitary pathological findings in horses with pituitary pars intermedia dysfunction: a retrospective study. J Equine Vet Sci 2009, 29:146-153.
58. Keen J.A., McLaren M., Chandler K.J., et al. Biochemical indices of vascular function, glucose metabolism and oxidative stress in horses with equine Cushing's disease. Equine Vet J 2004, 36:226-229.
59. McFarlane D., Cribb A.E. Systemic and pituitary pars intermedia antioxidant capacity associated with pars intermedia oxidative stress and dysfunction in horses. Am J Vet Res 2005, 66:2065-2072.
60. Conway K.A., Lee S.J., Rochet J.C., et al. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci U S A 2000, 97:571-576.
61. Betarbet R., Canet-Aviles R.M., Sherer T.B., et al. Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Neurobiol Dis 2006, 22:404-420.
62. Kirik D., Rosenblad C., Burger C., et al. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J Neurosci 2002, 22:2780-2791.
63. Good P.F., Hsu A., Werner P., et al. Protein nitration in Parkinson's disease. J Neuropathol Exp Neurol 1998, 57:338-342.
64. Cuervo A.M., Stefanis L., Fredenburg R., et al. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 2004, 305:1292-1295.
65. Narici M.V., Maffulli N. Sarcopenia: characteristics, mechanisms and functional significance. Br Med Bull 2010, 95:139-159.
66. Sakuma K., Yamaguchi A. Molecular mechanisms in aging and current strategies to counteract sarcopenia. Curr Aging Sci 2010, 3:90-101.
67. Aleman M., Nieto J.E. Gene expression of proteolytic systems and growth regulators of skeletal muscle in horses with myopathy associated with pituitary pars intermedia dysfunction. Am J Vet Res 2010, 71:664-670.
68. Pleasure D.E., Walsh G.O., Engel W.K. Atrophy of skeletal muscle in patients with Cushing's syndrome. Arch Neurol 1970, 22:118-125.
69. Tice L.W., Engel A.G. The effects of glucocorticoids on red and white muscles in the rat. Am J Pathol 1967, 50:311-333.
70. Lim S., Kim J.H., Yoon J.W., et al. Sarcopenic obesity: prevalence and association with metabolic syndrome in the Korean Longitudinal Study on Health and Aging (KLoSHA). Diabetes Care 2010, 33:1652-1654.
71. Geor R.J. Pasture-associated laminitis. Vet Clin North Am Equine Pract 2009, 25:39-50. vi.
72. Carter R.A., Treiber K.H., Geor R.J., et al. Prediction of incipient pasture-associated laminitis from hyperinsulinaemia, hyperleptinaemia and generalised and localised obesity in a cohort of ponies. Equine Vet J 2009, 41:171-178.
73. McGowan C.M., Frost R., Pfeiffer D.U., et al. Serum insulin concentrations in horses with equine Cushing's syndrome: response to a cortisol inhibitor and prognostic value. Equine Vet J 2004, 36:295-298.
74. de Laat M.A., McGowan C.M., Sillence M.N., et al. Equine laminitis: induced by 48 h hyperinsulinaemia in Standardbred horses. Equine Vet J 2010, 42:129-135.
75. Asplin K.E., Sillence M.N., Pollitt C.C., et al. Induction of laminitis by prolonged hyperinsulinaemia in clinically normal ponies. Vet J 2007, 174:530-535.
76. Johnson P.J., Ganjam V.K., Slight S.H., et al. Tissue-specific dysregulation of cortisol metabolism in equine laminitis. Equine Vet J 2004, 36:41-45.
77. Schott H., Graves E., Refsal K.R., et al. Diagnosis and treatment of pituitary pars intermedia dysfunction (classical Cushing's disease) and metabolic syndrome (peripheral Cushing's syndrome) in horses. Advances in veterinary dermatology 2004, 159-169. Blackwell Publisher, Oxford (UK), [Conference Proceedings]. A. Hillier, A.P. Foster, K.W. Kwochka (Eds.).
78. MacKay R.J. Quantitative intradermal terbutaline sweat test in horses. Equine Vet J 2008, 40:518-520.
79. van der Kolk J.H., Wensing T., Kalsbeek H.C., et al. Laboratory diagnosis of equine pituitary pars intermedia adenoma. Domest Anim Endocrinol 1995, 12:35-39.
80. Carter R.A., Geor R.J., Burton S.W., et al. Apparent adiposity assessed by standardised scoring systems and morphometric measurements in horses and ponies. Vet J 2009, 179:204-210.
81. Frank N., Elliott S.B., Brandt L.E., et al. Physical characteristics, blood hormone concentrations, and plasma lipid concentrations in obese horses with insulin resistance. J Am Vet Med Assoc 2006, 228:1383-1390.
82. McFarlane D., Hale G.M., Johnson E.M., et al. Fecal egg counts after anthelmintic administration to aged horses and horses with pituitary pars intermedia dysfunction. J Am Vet Med Assoc 2010, 236:330-334.
83. McFarlane D., McDaniel K. Neutrophil function in healthy aged horses and horses with pituitary dysfunction [abstract]. J Vet Intern Med 2010, 24:688-689.
84. Dybdal N.O., Hargreaves K.M., Madigan J.E., et al. Diagnostic testing for pituitary pars intermedia dysfunction in horses. J Am Vet Med Assoc 1994, 204:627-632.
85. Fazio E., Medica P., Aronica V., et al. Circulating beta-endorphin, adrenocorticotrophic hormone and cortisol levels of stallions before and after short road transport: stress effect of different distances. Acta Vet Scand 2008, 50:6.
86. Nagata S., Takeda F., Kurosawa M., et al. Plasma adrenocorticotropin, cortisol and catecholamines response to various exercises. Equine Vet J Suppl 1999, 30:570-574.
87. Beech J., Garcia M. Hormonal response to thyrotropin-releasing hormone in healthy horses and in horses with pituitary adenoma. Am J Vet Res 1985, 46:1941-1943.
88. Orth D.N., Nicholson W.E. Bioactive and immunoreactive adrenocorticotropin in normal equine pituitary and in pituitary tumors of horses with Cushing's disease. Endocrinology 1982, 111:559-563.
89. Beech J., Boston R., Lindborg S., et al. Adrenocorticotropin concentration following administration of thyrotropin-releasing hormone in healthy horses and those with pituitary pars intermedia dysfunction and pituitary gland hyperplasia. J Am Vet Med Assoc 2007, 231:417-426.
90. Miller M.A., Pardo I.D., Jackson L.P., et al. Correlation of pituitary histomorphometry with adrenocorticotrophic hormone response to domperidone administration in the diagnosis of equine pituitary pars intermedia dysfunction. Vet Pathol 2008, 45:26-38.
91. Sojka JE, Jackson LP, Moore G, et al. Domperidone causes an increase in endogenous ACTH concentration in horses with pituitary pars intermedia dysfunction (equine Cushing's disease). In: Proceedings of the 52nd Annual Convention of the American Association of Equine Practitioners. 2006. p. 320-3.
92. Douglas R. Circadian cortisol rhythmicity and equine Cushing's-like disease. J Equine Vet Sci 1999, 19:684-753.
93. Schott H, Pease A, Patterson J, et al. CT and MR imaging of equine pituitary glands. In: Proceedings of the 28th Annual Forum of the American College of Veterinary Internal Medicine. 2010. p. 196.
94. van der Kolk J.H., Heinrichs M., van Amerongen J.D., et al. Evaluation of pituitary gland anatomy and histopathologic findings in clinically normal horses and horses and ponies with pituitary pars intermedia adenoma. Am J Vet Res 2004, 65:1701-1707.
95. Baseman D.G., O'Suilleabhain P.E., Reimold S.C., et al. Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology 2004, 63:301-304.
96. Available at:, Accessed July, 2010. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108877.htm.
97. Davis J.L., Kirk L.M., Davidson G.S., et al. Effects of compounding and storage conditions on stability of pergolide mesylate. J Am Vet Med Assoc 2009, 234:385-389.
98. Gille G., Rausch W.D., Hung S.T., et al. Pergolide protects dopaminergic neurons in primary culture under stress conditions. J Neural Transm 2002, 109:633-643.
99. Uberti D., Piccioni L., Colzi A., et al. Pergolide protects SH-SY5Y cells against neurodegeneration induced by H(2)O(2). Eur J Pharmacol 2002, 434:17-20.
100. Thalamas C., Rajman I., Kulisevsky J., et al. Pergolide: multiple-dose pharmacokinetics in patients with mild to moderate Parkinson disease. Clin Neuropharmacol 2005, 28:120-125.
101. Wright A.M. Pharmacokinetics of pergolide in normal mares 2009, [master's thesis], Kansas State University, Manhattan (NY).
102. Singh D., Goel R.K. Proconvulsant potential of cyproheptadine in experimental animal models. Fundam Clin Pharmacol 2010, 24:451-455.
103. Beech J. Comparison of Vitex agnus castus extract and pergolide in treatment of equine Cushing's syndrome. In: Proceedings of the 48th Annual Convention of the American Association of Equine Practitioners. 2002. p. 175-7.